Form 4: Neumora Officer Granted 750,000 Stock Options

Neumora Therapeutics' Chief Legal and Administrative Officer, Jason Duncan, was granted 750,000 stock options with an exercise price of $2.33, vesting over four years.

Summary

• Jason Duncan, Chief Legal and Administrative Officer of Neumora Therapeutics, Inc. (NMRA), was granted 750,000 stock options.
• The stock options have an exercise price of $2.33 per share.
• The transaction date for this grant was January 8, 2026.
• The options have an expiration date of January 8, 2036.
• The vesting schedule dictates that 25% of the shares subject to the option vest on the first anniversary of January 8, 2026 (the 'Vesting Commencement Date').
• Following the initial 25% vesting, 1/48th of the total number of shares will vest monthly thereafter.
• The options will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a Form 4 is primarily a factual disclosure, the grant of significant stock options to a key executive indicates management's continued commitment and alignment with shareholder interests. It's a standard, positive incentive mechanism, though it doesn't directly reflect operational performance.

Positives

• The grant of stock options aligns the executive's long-term financial interests with those of the shareholders, incentivizing sustained company performance and value creation.
• This compensation structure is a common tool for executive retention, ensuring key management personnel remain committed to the company's strategic objectives.

Negatives

• The future exercise of these options could lead to dilution for existing shareholders, although this is a standard consideration for equity-based compensation plans.
• The value of the options is contingent on the company's stock price appreciating above the exercise price, introducing market-based risk for the executive.

Risks

• Market Price Risk: The value of the stock options is directly tied to the future market price of Neumora Therapeutics' common stock. If the stock price does not rise above the $2.33 exercise price, the options may hold no intrinsic value.
• Forfeiture Risk: The options are subject to a vesting schedule, meaning they could be forfeited if the executive's employment with Neumora Therapeutics terminates before the vesting conditions are fully met.
• Dilution Risk: Upon exercise, the issuance of new shares could dilute the ownership percentage of existing shareholders.

Future Outlook

This stock option grant is a forward-looking incentive designed to motivate the Chief Legal and Administrative Officer to contribute to the long-term growth and success of Neumora Therapeutics. The multi-year vesting schedule encourages sustained performance and commitment, aligning the executive's future compensation with the company's stock performance over the next four years.

Management Comments

• No direct management comments are typically included in a Form 4 filing, which is a transactional report.

Industry Context

The grant of stock options to key executives is a standard and widely adopted practice in the biotechnology and pharmaceutical industries. This form of equity compensation is crucial for attracting, retaining, and motivating top talent in a highly competitive sector, particularly for growth-oriented companies like Neumora Therapeutics, where long-term value creation is paramount.

Comparison to Industry Standards

• The grant of 750,000 stock options with a multi-year vesting schedule and an exercise price is a common and competitive practice for executive compensation in the biotechnology and pharmaceutical sectors.
• Similar equity incentive programs are observed at comparable companies such as Biogen or Vertex Pharmaceuticals, which utilize stock options and restricted stock units to retain talent and incentivize long-term value creation.
• The vesting schedule, with an initial cliff and subsequent monthly vesting, is a standard mechanism to ensure executive commitment over several years, aligning with typical industry benchmarks for executive equity grants.

Corporate Governance

Related Party Transactions

• The grant of stock options to Jason Duncan, an officer of Neumora Therapeutics, is considered a related party transaction. This is a standard form of executive compensation and is disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: Potential for long-term value creation if the executive's incentives lead to increased stock performance, balanced against potential future dilution from option exercise.
• Employees: Reflects a standard compensation practice that can be seen as competitive within the industry, potentially impacting morale and retention for other key personnel.
• Management: Provides a significant long-term incentive for the Chief Legal and Administrative Officer, aligning their financial success with the company's performance.

Next Steps

• The stock options will begin to vest on the first anniversary of January 8, 2026, with subsequent monthly vesting.
• Jason Duncan may choose to exercise vested options at any point before the expiration date of January 8, 2036, assuming the stock price is favorable.

Key Dates

Recommendation

This Form 4 reports a routine executive stock option grant, which is a standard compensation practice designed to align management incentives with shareholder interests. It does not provide new information that would alter the fundamental investment thesis for Neumora Therapeutics, hence a 'hold' recommendation is appropriate based solely on this filing. Investors should continue to evaluate the company based on its operational performance, clinical pipeline, and broader market conditions.

Keywords

Neumora Therapeutics, NMRA, Stock Option, Executive Compensation, Insider Transaction, Equity Grant, Form 4, Jason Duncan, Vesting Schedule